{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-057078","form_type":"8-K","ticker":"CBIO","cik":"0001253689","company_name":"CRESCENT BIOPHARMA, INC.","filed_at":"2025-06-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.762491+00:00","generated_at":"2026-05-19T18:06:40.547755+00:00","sec_items":["5.07","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Stockholders approve merger with Crescent Biopharma; 1-for-100 reverse split","bullets":["Stockholders approved all 10 proposals including merger agreement, stock issuance, charter amendments, reverse split, and equity plans.","Board approved 1-for-100 reverse stock split; outstanding shares reduced from ~64.5M to ~0.6M.","Post-merger combined company to trade as Crescent Biopharma, Inc. (CBIO) on Nasdaq starting June 16, 2025.","Combined company expected to have ~14.8M shares outstanding (~25.3M fully diluted) post-merger."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-057078","json":"https://secwatch.observer/filing/0001104659-25-057078.json","markdown":"https://secwatch.observer/filing/0001104659-25-057078.md","text":"https://secwatch.observer/filing/0001104659-25-057078.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1253689/000110465925057078/0001104659-25-057078-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1253689/000110465925057078/tm2517051d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T18:06:40.547755+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}